Five things you need to know today, Feb. 8

first_imgHome Local News Five things you need to know today, Feb. 8 2021 SCHOOL HONORS: Permian High School Local News Five things you need to know today, Feb. 8 Facebook From left, Diana Ako and Aryalli Gonzales, both 2-years-old, paint their boxes. Kids at the Odessa Day Nursery make Valentine boxes during the arts and crafts time. Odessa Day Nursery is one of the agencies helped by the United Way. By admin – February 8, 2018 WhatsApp Twitter Previous articleSeven candidates vie for JP officeNext articleOdessa police investigating shooting in the 2400 block of Oakwood admin RELATED ARTICLESMORE FROM AUTHOR Take a look at the news in and around Odessa on Thursday, Feb. 8. Find complete local news coverage in the Odessa American every day, online at oaoa.com and our daily E-Edition at myoaoa.com.1. The Odessa City Council will consider hiring an outside law firm to fill in as the full-time city attorney after the retirement of Larry Long, who was allowed to retire at the end of this month following a sexual harassment complaint corroborated by the city’s human resources department.2. Voters are going to have a plethora of names to sort through in the upcoming March primary, particularly in the race for the Ector County Precinct 2 Justice of the Peace position, which has seven different candidates vying for the vacant seat.3. With just one week left in their fundraising campaign, United Way of Odessa is working hard to reach their $2 million goal to ensure they have the money to provide to the local agencies they help support.4. A woman was charged with endangering a child she was babysitting after reportedly dragging her out of bed outside into 37 degree weather.5. IN SPORTS: Three Permian athletes made their college choices official Wednesday by signing national letters of intent at the Permian High School library.center_img Twitter OC employee of the year always learning WhatsApp Facebook ECISD undergoing ‘equity audit’ Creamy Fruit SaladTexas Fried ChickenSmoked Bacon Wrapped French Vidalia OnionPowered By 10 Sec Croissant Breakfast Sandwich Casserole NextStay Pinterest Pinterestlast_img read more

Commissioners to appoint new county judge

first_img Facebook Commissioners to appoint new county judge Pinterest Facebook WhatsApp Pinterest Previous articleTHE IDLE AMERICAN: Marriage vows in concreteNext articleAnnual Daddy Daughter Dance admin By admin – June 10, 2018 center_img WhatsApp Twitter Local NewsGovernment Twitter Commissioners court logo Previous coverageA changing of the guard will take place Monday during the next commissioners’ court as County Judge Ron Eckert will hand off Ector County’s top administrative position to Debi Hays.The meeting is at 10 a.m. in the commissioners’ courtroom located in the Ector County Administration building annex, 1010 E. Eighth St.Eckert’s resignation was announced in the meeting agenda, which was released more than a week before the meeting. He will be leaving to begin a new job as vice president and general counsel at a local gas and oil service company. He did not seek re-election.The decision to leave was made following commissioner’s rejecting Eckert’s proposal to pursue taking on $85 million of debt for a new courthouse, which only Eckert and Precinct 1 Commissioner Eddy Shelton supported.“When I couldn’t solve the problem, what more sense does it make to stay?” Eckert said previously. “It’s better to get out in time for the next judge to put her own stamp on the budget.”Hays will be coming into the position a little more than a month before she has to submit a budget for the 2019 fiscal year, and said she is feeling positive coming into the position, calling the budget her No. 1 priority.I work better under pressure and with constant challenges on the blackboard,” Hays said previously. “Let’s make a to-do list and let’s mark them off.”Hays became the de facto next County Judge after besting Chris Fostel in the March Republican primary, and not having a Democratic challenger to run against in November.Also during the meeting, Missi Walden will be appointed to Precinct 2 Justice of the Peace, a position she was elected to following the May runoff where she beat Matt Stringer to fill the vacant seat.IN OTHER BUSINESS, COMMISSIONERSWill present a Certificate of Completion to Precinct 1 Commissioner Eddy Shelton for County Commissioners Court Leadership Academy Class VII from V.G. Young Institute of County Government.Will consider a proposed ban of rockets with sticks and missiles with fins for the 4th of July fireworks season.Will accept a donation of $85,000 from Bustin for Badges for the Sheriff’s Office.Will accept a donation of $1,000 from Adriana and Marcos Lujan for the purchase of a tactical vest for the Sheriff’s Office.Will consider a proposed resolution adopting a temporary 207 (k) exemption two-week work period of 86 hours and to compensate overtime with paid overtime after 86 hours for jailers, but retaining the current 207 (k) exemption work period of 28 days and overtime earned after 171 hours with overtime paid in the form of compensatory time off for all other law enforcement.Will appoint Gus Ortega to the Board of Trustees for Permian Basin Community Centers for a two-year term running from June 27, 2018 to June 26, 2020.Will consider the competitive proposal and contract for the roof repair—phase 1 project.Will consider the evidence/forensics building competitive sealed proposal specifications.Will consider the Ector County Law Enforcement Center—tilt skillets to be purchased with the jail expansion funds—special departmental equipment, and authorize a budget amendment from jail expansion funds, improvements and construction to jail expansion funds, special departmental equipment in the amount of $30,007.Will consider the proposal/letter of agreement for the ECLEC—abandoned vehicle and forensics storage building with JSA Architects to be funded from jail expansion fund, professional services for $42,000.Will consider the proposed AIA change order No. 8 for the jail additions and renovations project.Will consider a proposed amendment to the Lexis Advance Subscription Agreement between LexisNexis and Ector County, for research services for the County Law Library.Will consider a proposed interlocal agreement between the Office of the Attorney General and Ector County, for the purposes of issuing 10 licenses to the Office of the Attorney General for the purpose of allowing the Office of the Attorney General to access the County Odyssey Integrated Courts and Justice System.Will consider the proposed Angel Subdivision being 50.1 acres out of section 18, block 43, T-2-S, T&P RY. CO. Survey.Will consider a requested letter of support for a grant proposal to be submitted by Permian Basin Community Centers for a matching grant for justice-involved individuals as directed by Senate Bill 292.Will consider the proposed replat of lot 5, block 2, Brown Industrial sites, having a tract site of 5.05 acres.Will consider the proposed replat of 8.05 acres out of tract 9, Belmont Acres.Will consider the proposed replat of lot 8, block 3, Pleasant Farms subdivision, first filing.Will receive the Accounts Payable Fund Requirements Report for June 11, 2018.last_img read more

ISACA publica novo relatório sobre tendências, obstáculos e previsões em matéria de privacidade às…

first_img Pinterest Facebook By Digital AIM Web Support – January 26, 2021 Local NewsBusiness Pinterest TAGS  SCHAUMBURG, Illinois–(BUSINESS WIRE)–jan 26, 2021– Ao se aproximar do Dia da Privacidade de Dados nesta semana, a ISACA lançou um novo relatório de pesquisa, Privacy in Practice 2021: O Data Privacy Trends, Forecasts and Challenges (Privacidade na prática 2021: tendências, previsões e desafios em privacidade de dados), que analisa tendências passadas e futuras em privacidade planejada, obstáculos para a privacidade e força de trabalho de privacidade. Este comunicado de imprensa inclui multimédia. Veja o comunicado completo aqui: https://www.businesswire.com/news/home/20210126005952/pt/ The current privacy landscape is rife with low investment, lack of high-level prioritization and lack of skilled privacy professionals that leave organizations open to penalties and loss of reputation. ISACA, a global professional association and learning organization, surveyed more than 1,800 IT audit, risk, security and privacy professionals on privacy workforce trends and skills gaps, privacy programs, and the regulations and frameworks that guide privacy programs. (Graphic: Business Wire) Privacidade planejada Empresas que informam que utilizam sempre a privacidade planejada (privacy by design) tendem a ser mais orientadas por uma combinação de conformidade e ética (62% em comparação com 52% no total). Elas também são quase 2,5 vezes mais propensas a ter total confiança na capacidade de suas equipes de privacidade de assegurar a privacidade de dados e atingir a conformidade com novas leis e regulamentações de privacidade (24% em comparação com 10% no total). No entanto, não foi identificada uma diferença significativa na quantidade de violações de privacidade sofridas por elas nos últimos 12 meses na comparação com todas as pesquisadas. Aproximadamente 10% de ambos os grupos relataram violações, um número que possivelmente indica subnotificações. Obstáculos para a privacidade As organizações pesquisadas identificaram outras falhas comuns de privacidade, entre elas:Falta de treinamento ou treinamento deficiente (64%)Falha ao realizar uma análise de riscos (53%)Detecção deficiente ou inexistente de informações pessoais (50%) As pesquisadas citaram estruturas de princípios de privacidade, dados de acesso com base em experiência e treinamento de privacidade como os métodos mais úteis para superar esses obstáculos. Tendências de força de trabalho As organizações pesquisadas indicaram que preveem maior demanda por cargos técnicos de privacidade em comparação com cargos jurídicos e de conformidade (alta de 70% em comparação com alta de 59%). Entretanto, cargos técnicos de privacidade foram mais propensos a ser considerados com falta de pessoal (46% em comparação com 33%). Contudo, gerentes de contratação têm ocupado esses cargos por meio de treinamento; 47% observaram que vêm treinando profissionais que não trabalhavam com privacidade, mas têm interesse em ocupar cargos nessa área. 92% das organizações pesquisadas indicaram que contam com profissionais de privacidade que iniciaram suas carreiras em TI ou segurança, e migraram para as áreas de privacidade e conformidade. “As organizações continuarão precisando de uma sólida força de trabalho de privacidade nos próximos anos”, afirma Nader Qaimari, diretor de produto da ISACA. “O aumento nas oportunidades de capacitação para essa trilha de carreira e competências técnicas por parte de profissionais não provenientes da área de privacidade não só reduz as deficiências de privacidade, mas também enriquece essa força de trabalho”. O webinar gratuito “Exploring Privacy Trends, Challenges & Predictions” (Explorando tendências, desafios e previsões em privacidade) às 12h (EST)/17h (UTC) de 28 de janeiro de 2021 abordará os destaques da pesquisa. Para saber mais, acesse www.isaca.org/education/online-events/lms—w012821. Acesse o relatório da pesquisa Privacidade na prática 2021 em www.isaca.org/privacy-in-practice-2021. Saiba mais sobre os recursos de privacidade da ISACA, inclusive a certificação Certified Data Privacy Solutions Engineer™ (CDPSE™), em www.isaca.org/cdpse. Sobre a ISACA Há mais de 50 anos, a ISACA® ( www.isaca.org ) mune pessoas de conhecimentos, credenciais, formação educacional e comunidade para promoverem suas carreiras e transformarem suas organizações, além de possibilitar que empresas capacitem e desenvolvam equipes de qualidade. A ISACA emprega a experiência e os conhecimentos de mais de 150 mil membros que trabalham em segurança da informação, governança, garantia, riscos e privacidade para promover inovação por meio da tecnologia. Ela está presente em 188 países e possui mais de 220 filiais. O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal. Ver a versão original em businesswire.com:https://www.businesswire.com/news/home/20210126005952/pt/ CONTACT: Emily Van Camp, +1.847.385.7217,[email protected] Kristen Kessinger, +1.847.660.5512,[email protected] KEYWORD: EUROPE UNITED STATES NORTH AMERICA CANADA ILLINOIS INDUSTRY KEYWORD: SOFTWARE MOBILE/WIRELESS NETWORKS INTERNET ELECTRONIC DESIGN AUTOMATION DATA MANAGEMENT TECHNOLOGY OTHER EDUCATION CONTINUING SECURITY EDUCATION OTHER TECHNOLOGY SOURCE: ISACA Copyright Business Wire 2021. PUB: 01/26/2021 01:04 PM/DISC: 01/26/2021 01:04 PM http://www.businesswire.com/news/home/20210126005952/pt Twittercenter_img WhatsApp Previous articleMetLife to Provide Annuity Benefits to 13,500 Lockheed Martin Retirees and BeneficiariesNext articleUne nouvelle étude conclut que Xlear élimine et/ou désactive le SRAS-CoV-2 ; Efficacité contre les nouveaux variants Digital AIM Web Support ISACA publica novo relatório sobre tendências, obstáculos e previsões em matéria de privacidade às vésperas do Dia da Privacidade de Dados Facebook WhatsApp Twitterlast_img read more

New Study Confirms PhoneSoap ExpressPro Disinfection Technology Kills 99.99% of SARS-CoV-2 Virus

first_imgLocal NewsUS News TAGS  By Digital AIM Web Support – January 29, 2021 WhatsApp Facebook Previous articleGlobal Home Outdoor Pest Control Devices Market Research 2020-2024 | Industry Planning Structure | TechnavioNext articlePiedmont Lithium Limited: December 2020 Quarterly Report Digital AIM Web Support Twitter Facebookcenter_img Pinterest Pinterest PROVO, UTAH, Jan. 29, 2021 (SEND2PRESS NEWSWIRE) — PhoneSoap proudly announces a 99.99% reduction of SARS-CoV-2 with its ExpressPro disinfection technology. According to a recent study conducted by the University of Tennessee Health Science Center, the PhoneSoap ExpressPro, a rapid UV disinfection device for cell phones, tablets, and other hard-to-clean hand-held items, resulted in a 99.99% reduction of SARS-CoV-2 during the 30-second cycle time. PhoneSoap ExpressPro is a rapid UV disinfection device for busy work environments utilizing mobile devices such as cell phones, tablets, and other hard-to-clean hand-held items. The rapid 30-second, 360-degree  disinfection that is the hallmark of the PhoneSoap brand, makes it an invaluable tool for many industries including healthcare, hospitality, education, and travel. “We’re extremely pleased with the outcome of this third-party SARS-CoV-2 study and recognize how critical it is to break the chain of infection,” stated Wesley LaPorte, Co-Founder and CEO of PhoneSoap. “Whatever your hands touch, your hand-held devices collect and that includes  this deadly virus which is known to survive for extended periods of time on common surfaces. We refer to these mobile devices as the third hand you never wash, but PhoneSoap’s ExpressPro provides an easy and fast way to disinfect them and help stop the spread of infection.” Dan Barnes, PhoneSoap Co-founder and President, expressed “Dramatic reductions in infection-causing microorganisms such as the 99.99% with the SARS-Co-V-2 virus along with a 99.999% reduction of MRSA and 99.9% of C. difficile, allow our healthcare, retail and other customers to mitigate the risk of transmission in their respective businesses. We’re proud that we are continuing in our mission of making the world a healthier place.” Learn more about PhoneSoap ExpressPro at:  https://www.pro.phonesoap.com ABOUT PHONESOAP: PhoneSoap was invented by cousins Dan Barnes and Wes LaPorte after they watched a TV report that claimed cell phones were contaminated by fecal matter. They conducted their own tests, their results proved that the average phone is 18 times dirtier than a public bathroom. After appearing on season six of Shark Tank in 2015 and making a deal with QVC’s Lori Greiner, PhoneSoap took off. In addition to ExpressPro, the company has since developed new versions of its classic PhoneSoap, including Wireless and HomeSoap versions. PhoneSoap’s focus continues to be making the world a healthier place. Learn more at: https://www.phonesoap.com/ *PHOTO link for media: https://www.Send2Press.com/300dpi/21-0129s2p-phonesoap-300dpi.jpg *Caption: Motion-activated door and touchless operation to eliminate cross-transmission. MEDIA ONLY CONTACTS Kelli Sprunt Marketing Manager [email protected] Denise Graham denis[email protected] (202)294-6314 NEWS SOURCE: PhoneSoap This press release was issued on behalf of the news source (PhoneSoap) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: 67904 APDF-R8.2 © 2021 Send2Press®, a press release and e-marketing service of NEOTROPE®, Calif., USA. To view the original version, visit: https://www.send2press.com/wire/new-study-confirms-phonesoap-expresspro-disinfection-technology-kills-99-99-of-sars-cov-2-virus/ Disclaimer: This press release content was not created by the Associated Press (AP). Twitter WhatsApp New Study Confirms PhoneSoap ExpressPro Disinfection Technology Kills 99.99% of SARS-CoV-2 Viruslast_img read more

M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board

first_imgLocal NewsBusiness Twitter By Digital AIM Web Support – February 3, 2021 Pinterest TAGS  Previous articleSilicon Labs: 4Q Earnings SnapshotNext articleXL Fleet Corp. Announces Timing of Fourth Quarter and Full Year 2020 Earnings Release and Conference Call Digital AIM Web Support WhatsApp M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Boardcenter_img ST. LOUIS–(BUSINESS WIRE)–Feb 3, 2021– M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its scientific advisory board (SAB) that will support the Company’s mission of translating its innovative bicistronic-S1S3 technology platform into best-in-class therapies that address unmet needs within the LSD community. The Company’s platform enables improved biodistribution of recombinant enzymes to target tissues and efficient cross-correction for gene therapies. “As we work to advance our robust pipeline, we seek the input and support of a world-class team of scientific advisors with deep expertise in genetics, rare diseases, and lysosomal storage and metabolic disorders in particular,” said Pawel Krysiak, president and chief executive officer of M6P Therapeutics. “The collective insights, knowledge, commitment, and expertise of our scientific advisory board will help us translate this high science into potential medical benefit for the individuals affected by these serious conditions.” By combining the substantial expertise of the SAB with the expertise of the Company’s internal R&D team in recombinant enzyme and gene therapies, M6P Therapeutics is well positioned to rapidly advance its deep pipeline of LSD programs. The members of the SAB are:Stuart Kornfeld, MD, is a co-founder of M6P Therapeutics, the chairman of its SAB, and a professor in the Department of Medicine and the Department of Biochemistry and Molecular Biophysics at Washington University Medical School. Dr. Kornfeld has devoted decades to understanding mannose 6-phosphate (M6P) and its importance in lysosomal protein trafficking, and he is considered the leading expert on this subject matter. He has advised multiple companies working on LSDs.Nancy Dahms, PhD, is a Professor of Biochemistry at the Medical College of Wisconsin. She received her doctorate degree from Johns Hopkins University School of Medicine where she studied site-specific N-glycosylation. As a postdoctoral fellow at Washington University School of Medicine, she isolated and characterized cDNA clones for the M6P receptors involved in targeting lysosomal enzymes to the lysosome. A glycobiologist and biochemist, Dr. Dahms investigates glycan-binding proteins in the secretory pathway. Her research has defined the molecular basis for the recognition of lysosomal enzymes by the M6P receptors. Dr. Dahms has developed a rat model for Fabry disease to aid in revealing pathogenic mechanisms of this common LSD.Gregory Enns, MD, is a Professor of Pediatrics and Genetics at the Lucile Salter Packard Children’s Hospital Stanford School of Medicine. Dr. Enns’ research interests include novel means of diagnosing and treating mitochondrial disorders, with an emphasis on antioxidant therapy, lysosomal disorders, and newborn screening by tandem mass spectrometry. His current pursuits include the analysis of glutathione and antioxidant status in patients who have mitochondrial disorders and the development of new techniques for diagnosing these conditions.Mark S. Sands, PhD, is a Professor in the Departments of Medicine and Genetics at Washington University School of Medicine in St. Louis. Dr. Sands received his PhD in Molecular Pharmacology from the State University of New York at Stony Brook. He was a postdoctoral fellow at The Jackson Laboratory (Bar Harbor, ME) and at the University of Pennsylvania School of Veterinary Medicine before joining the faculty at Washington University School of Medicine. The goals of Dr. Sands laboratory are to better understand the underlying pathogenesis and developing effective therapies for inherited childhood diseases, specifically LSDs. A major focus of his group is to determine the safety and efficacy of adeno-associated viral gene transfer vectors for the treatment of both the CNS and systemic manifestations of these diseases. In addition, his group has developed lentiviral-mediated hematopoietic stem cell-directed gene therapy approaches, as well as small molecule drugs, and more recently rational combinations of these approaches. The primary diseases that Dr. Sands studies are mucopolysaccharidosis type VII (MPS VII), Krabbe disease, and Infantile Neuronal Ceroid Lipofuscinosis.Anna Tylki-Szymanska, MD, is a Professor, Department of Pediatrics and Pediatric Metabolic and Genetic Medicine at the Children’s Memorial Health Institute, Department of Metabolic Diseases in Warsaw, Poland. In the field of metabolic diseases, Prof. Tylki-Szymańska’s interests are focused mainly on lysosomal diseases. She has specialized for 30 years at the Department of Metabolic Diseases, which is the only referral center in Poland for inborn errors of metabolism. Prof. Tylki-Szymańska’s research interests are directed particularly on neurometabolic and neurodevelopmental diseases. She is especially interested in developing diagnostic assays and new approaches for the treatment of lysosomal diseases. She was a principal investigator for the recombinant enzyme replacement clinical trials for Gaucher, Fabry, MPS II and substrate inhibition therapy trials for MPS III, LAL deficiency and Gaucher disease. Prof. Tylki-Szymańska is a winner of the Order of the Smile. Order of the Smile is an international award given by children, to adults distinguished in their love, care, and aid for children.Raymond Wang, MD, is the Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s, Associate Professor, Pediatrics, UC, Irvine School of Medicine. Dr. Wang is also a board-certified clinical geneticist and biochemical genetics specialist. He is investigating the role of inflammation and the innate immune system, triggered by arterial lysosomal storage, in promoting MPS cardiovascular disease, and identifying novel therapeutic methods to address treatment-refractory cardiovascular disease in MPS. He also actively works on other research projects related to Niemann-Pick C Disease, Pompe, Hunter, and Sanfillipo Syndrome. “M6P Therapeutics’ bicistronic-S1S3 technology platform enhances mannose 6-phosphate content on lysosomal enzymes for both recombinant enzyme and gene therapies, which improves enzyme uptake across target tissues,” said Stuart Kornfeld, MD, M6P Therapeutics’ co-founder and chairman of its SAB. “With promising pre-clinical data across numerous LSD programs, this innovation can potentially translate into new and more efficacious treatments, reduced immunogenicity, and more efficient dosing regimens.” About M6P Therapeutics M6P Therapeutics is a privately held, venture-backed biotechnology company developing the next-generation targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs). M6P Therapeutics’ proprietary bicistronic-S1S3 platform has the unique ability to enhance phosphorylation of lysosomal enzymes for both enzyme replacement and gene therapies leading to improved biodistribution and cellular uptake of recombinant proteins and efficient cross-correction of gene therapy product. This can potentially lead to more efficacious treatments with lower therapy burden, as well as new therapies for currently untreated diseases. M6P Therapeutics’ team, proven in rare diseases drug development and commercialization, is dedicated to fulfilling the promise of recombinant enzyme and gene therapies by harnessing the power of protein phosphorylation using its bicistronic-S1S3 platform. M6P Therapeutics’ mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community. For more information, please visit: www.m6ptherapeutics.com. View source version on businesswire.com:https://www.businesswire.com/news/home/20210203005284/en/ CONTACT: Contact us to learn about partnering opportunities with M6P Therapeutics: M6P Therapeutics: 314-236-9694 [email protected]: Alex Van Rees, SmithSolve 973-442-1555 x111 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MISSOURI INDUSTRY KEYWORD: HEALTH GENETICS OTHER SCIENCE RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: M6P Therapeutics Copyright Business Wire 2021. PUB: 02/03/2021 07:30 AM/DISC: 02/03/2021 07:31 AM http://www.businesswire.com/news/home/20210203005284/en Facebook Twitter Pinterest WhatsApp Facebooklast_img read more

Vendia Announces $15.5M Series A Funding and Launches Vendia Share™ for Developers

first_img Facebook TAGS  Vendia Share Sample UI Pinterest Previous articleAscom Secures Substantial US Distribution Agreement With Primary SystemsNext articleTechstars Los Angeles Accelerator Appoints Matt Kozlov as Techstars LA Managing Director Digital AIM Web Support Local NewsBusiness Twitter Facebookcenter_img WhatsApp Twitter WhatsApp By Digital AIM Web Support – February 3, 2021 Vendia Announces $15.5M Series A Funding and Launches Vendia Share™ for Developers Pinterestlast_img read more

Record Breaking Apartment Sale in Turlock by The Mogharebi Group

first_img WhatsApp Local NewsBusiness By Digital AIM Web Support – February 3, 2021 Previous articleBiden flexible on who gets aid, tells lawmakers to ‘go big’Next articleUniversal Electronics Inc. Introduces UEI Virtual Agent for Entertainment and Smart Home Devices Digital AIM Web Support Record Breaking Apartment Sale in Turlock by The Mogharebi Group Pinterest WhatsApp Facebook Twitter Facebook Pinterest Twitter TAGS  last_img read more

Western Digital to Participate in Upcoming Investor Conferences

first_img Event: Thursday, February 11, 2021 at 12:40 p.m. PT / 3:40 p.m. ET The virtual presentations will be available as a live webcast, accessible through Western Digital’s Investor Relations website at investor.wdc.com. An archived replay will be accessible through the website shortly after the conclusion of the presentation. About Western Digital Western Digital creates environments for data to thrive. As a leader in data infrastructure, the company is driving the innovation needed to help customers capture, preserve, access and transform an ever-increasing diversity of data. Everywhere data lives, from advanced data centers to mobile sensors to personal devices, our industry-leading solutions deliver the possibilities of data. Our data-centric solutions are comprised of the Western Digital ®, G-Technology ™, SanDisk ®, and WD ® brands. © 2021 Western Digital Corporation or its affiliates. All rights reserved. View source version on businesswire.com:https://www.businesswire.com/news/home/20210203005751/en/ CONTACT: Investor Relations Contact: Western Digital Corp. T. Peter Andrew +1-949-672-9655 [email protected] [email protected] Contact: Sard Verbinnen & Co John Christiansen David Isaacs Leah Polito [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SEMICONDUCTOR HARDWARE CONSUMER ELECTRONICS OTHER TECHNOLOGY TECHNOLOGY SOURCE: Western Digital Corp. Copyright Business Wire 2021. PUB: 02/03/2021 05:00 PM/DISC: 02/03/2021 05:01 PM http://www.businesswire.com/news/home/20210203005751/en Presentation: Twitter By Digital AIM Web Support – February 3, 2021 WhatsApp SAN JOSE, Calif.–(BUSINESS WIRE)–Feb 3, 2021– Western Digital Corp. (NASDAQ: WDC) today announced management participation in the upcoming investor conferences: TAGS  Pinterest Presentation: Facebook Twitter Pinterest Facebook WhatsApp Local NewsBusiness Event: Morgan Stanley Technology, Media and Telecom Conference Western Digital to Participate in Upcoming Investor Conferences Goldman Sachs Technology & Internet Conference 2021 Tuesday, March 2, 2021 at 8:45 a.m. PT / 11:45 a.m. ET Previous articleAmerican Financial Group, Inc. Announces Fourth Quarter and Full Year ResultsNext articleSki Report Digital AIM Web Supportlast_img read more

PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer

first_img Twitter PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer Previous articleNexthink Reaches $1.1 Billion Valuation with $180M in Series D Financing Round, Names Former Adobe CEO to its Board of DirectorsNext articleSarah Cannon Leaders to Present at the 2021 TCT Meetings of ASTCT® and CIBMTR® Digital AIM Web Support BOSTON–(BUSINESS WIRE)–Feb 8, 2021– PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, today announced the appointment of Mark Mullikin as Chief Financial Officer. Mr. Mullikin brings 25 years of experience raising and deploying capital for life sciences companies, and most recently held leadership roles in finance and investor relations at publicly-traded Editas Medicine and Novartis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005131/en/ Vedanta announced the appointment of Mark Mullikin as Chief Financial Officer. Mr. Mullikin brings 25 years of experience raising and deploying capital for life sciences companies, and most recently held leadership roles in finance and investor relations at publicly-traded Editas Medicine and Novartis. (Photo: Business Wire) Mr. Mullikin joins Vedanta from Editas Medicine, where he served as Vice President, Finance and Investor Relations and was involved in raising $700 million of equity capital. Prior to this role, Mr. Mullikin worked for Novartis in roles focused on financial and strategic planning in addition to health economics and pricing. Before joining Novartis, he was a healthcare equity analyst at Adage Capital Management and Piper Sandler and began his career in the finance and strategy practice at Deloitte Consulting. The full text of the announcement from Vedanta is as follows: Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer Extensive biotech finance and investor relations expertise includes leadership roles at Editas Medicine and Novartis CAMBRIDGE, MA, February 8, 2021 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced the appointment of Mark Mullikin as Chief Financial Officer. Mr. Mullikin brings 25 years of experience raising and deploying capital for life sciences companies, and most recently held leadership roles in finance and investor relations at publicly-traded Editas Medicine and Novartis. “Mark’s experience overseeing the finances of a public biotech and previously as a healthcare equity analyst, provide him a unique and broad perspective of the biotech field,” said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. “We are excited to welcome Mark to the Vedanta team and look forward to his contributions.” Mr. Mullikin joins Vedanta from Editas Medicine, where he served as Vice President, Finance and Investor Relations and was involved in raising $700 million of equity capital. Prior to this role, Mr. Mullikin worked for Novartis in roles focused on financial and strategic planning in addition to health economics and pricing. Before joining Novartis, he was a healthcare equity analyst at Adage Capital Management and Piper Sandler and began his career in the finance and strategy practice at Deloitte Consulting. Mr. Mullikin earned his M.B.A. in finance from the MIT Sloan School of Management and his B.A. in economics from the University of Chicago. “Vedanta has established a leadership position in the microbiome field pioneering defined bacterial consortia as a new class of therapeutics,” said Mr. Mullikin. “I am thrilled to join at this pivotal moment of growth with key clinical trial readouts anticipated this year.” About Vedanta Biosciences Vedanta Biosciences is leading the development of a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses . Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what is believed to be the world’s biggest library of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies and cGMP-compliant manufacturing of oral live biotherapeutics containing pure, clonally derived bacterial consortia in powdered form. Vedanta Biosciences was founded by PureTech Health (LSE: PRTC, Nasdaq: PRTC) and a global team of scientific co-founders who pioneered Vedanta’s modern understanding of the cross-talk between the microbiome and the immune system. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, as of the date of PureTech’s most recently filed Registration Statement on Form 20-F, was comprised of 24 products and product candidates, including two that have received FDA clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of our product candidates, our expectations regarding the appointment of Mark Mullikin as Chief Financial Officer and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005131/en/ CONTACT: Investors and Media Allison Mead Talbot +1 617 651 3156 [email protected]  KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH MEDICAL DEVICES SOURCE: PureTech Health plc Copyright Business Wire 2021. PUB: 02/08/2021 07:00 AM/DISC: 02/08/2021 07:01 AM http://www.businesswire.com/news/home/20210208005131/en TAGS  Pinterest WhatsApp Local NewsBusinesscenter_img By Digital AIM Web Support – February 8, 2021 WhatsApp Facebook Twitter Pinterest Facebooklast_img read more

KymetaTM étend ses solutions de nouvelle génération en lançant le terminal u8 GOV et…

first_img Twitter By Digital AIM Web Support – February 9, 2021 KymetaTM étend ses solutions de nouvelle génération en lançant le terminal u8 GOV et la mallette u8 GO Pinterest Pinterest Previous articleNational Geographic Taps Harry Hamlin (“Mad Men,” “Shameless”) and Dylan Baker (“The Good Wife,” “Hunters”) as Guest Stars Alongside Previously Announced Leads Tony Goldwyn and Daniel Dae Kim for THE HOT ZONE: ANTHRAXNext articleTafi Brings Daz 3D’s Massive 3D Content Library to Unity Digital AIM Web Support Facebook REDMOND, Washington–(BUSINESS WIRE)–févr. 9, 2021– Kymeta ( www.kymetacorp.com ) – la société de communication qui rend le mobile global – a annoncé aujourd’hui l’expansion et la disponibilité de son produit Kymeta TM u8, incluant le terminal u8 GOV de Kymeta avec un modem iDirect 950mp intégré et le terminal transportable u8 GO. Les terminaux u8 GOV de Kymeta sont conçus pour répondre aux besoins des gouvernements, et pour être utilisés dans un cadre militaire ou commercial spécialisé. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20210209006101/fr/ The u8 GOV terminal and u8 GO provide the complete connectivity solution for on-the-go communications. (Photo: Business Wire) Le terminal u8 GOV comprend un module FIPS, 140-2 de niveau 3 TRANSEC et répond aux demandes des utilisateurs tactiques dans des scénarios nécessitant une connectivité sécurisée des données, de la voix et de la vidéo dans des applications militaires, gouvernementales et autres applications hautement mobiles où une réponse rapide est nécessaire. Le terminal u8 GOV couvre toute la bande Ku et est disponible dès aujourd’hui en tant que produit clés en main doté d’un modem satellite, d’un modem cellulaire et de capacités SD-WAN. Il est conforme aux exigences de sécurité en vigueur telles que définies par le National Institute of Standards and Technology (NIST). « Les solutions de Kymeta répondent aux besoins critiques des militaires, des premiers intervenants et des clients commerciaux en fournissant une connectivité permanente pour les plateformes mobiles, rendant les communications au cours des déplacements plus fluides et plus fiables que jamais », a déclaré Rob Weitendorf, vice-président du développement commercial chez Kymeta. Également disponibles dès aujourd’hui, les terminaux transportables u8 GO sont proposés dans plusieurs configurations, y compris les terminaux ODU, Commercial et GOV, et peuvent être transportés en toute sécurité grâce à une mallette de transport renforcée et robuste qui assure leur protection. Ils sont fournis avec une fixation au véhicule intégrée pour faciliter les communications pendant les repos (communications on the pause, COTP) ainsi que les communications lors des déplacements (communications on-the-move, COTM). Cette configuration transportable, facilement maniable et idéale pour les déploiements rapides, a été testée par rapport aux normes de transport militaires, notamment MIL-STD-810H, Transit Drop, Transportation Shock et Loose Cargo Vibration. Le terminal u8 GO est fourni avec une alimentation extérieure de type CA/CC et prend en charge les communications pendant les repos (COTP) avec un mécanisme d’inclinaison à 25 degrés. Il peut par ailleurs être monté sur un véhicule pour un déploiement facile s’adaptant à une multitude de cas d’utilisation. Les solutions Kymeta u8, qui incluent désormais également le terminal u8 GOV et la mallette transportable u8 GO, offrent une solution de connectivité complète pour les communications lors des déplacements (COTM) et les réseaux lors des déplacements (networks-on-the-move, NOTM), vous permettant d’en bénéficier quand et là où vous en avez le plus besoin. Le terminal u8, doté de la technologie révolutionnaire de direction de faisceau électronique définie par logiciel de Kymeta, est discret et facile à monter sur les véhicules et les bateaux. Les solutions u8 clés en main sont disponibles dans plusieurs configurations de terminaux, permettant aux clients de disposer exactement du matériel, des logiciels et de la connectivité dont ils ont besoin. Kymeta a lancé son antenne, son terminal et ses services de nouvelle génération au quatrième trimestre 2020, et a reçu une réponse extrêmement positive de la part de l’industrie. Kymeta Connect™, le terminal u8 associé aux services de connectivité hybride satellite-cellulaire de Kymeta, transforme l’achat et la consommation des données mobiles grâce à un abonnement mensuel tout compris, incluant matériel, connectivité et services. Le Kymeta u8 est au niveau mondial la seule antenne à panneau plat pilotée électroniquement disponible dans le commerce bâtie spécifiquement pour la mobilité et conçue pour les besoins des militaires, des premiers intervenants et des clients commerciaux. À propos de Kymeta Kymeta libère le potentiel de la connectivité satellite à large bande, combinée aux réseaux cellulaires, pour satisfaire la demande massive de communications au cours des déplacements, et de globalisation de la téléphonie mobile. Lepton Global Solutions, une société de Kymeta, héberge les solutions de connectivité par satellite de la société, et offre au marché des solutions clés en main, uniques, complètes et groupées, basées sur les meilleures technologies, et des services sur mesure axés sur le client qui répondent aux exigences de mission de ces clients, et même les dépassent. Ces solutions, combinées à l’antenne satellite à panneau plat de la société, la première en son genre, et aux services Kymeta Connect™, fournissent aux clients du monde entier une connectivité mobile révolutionnaire sur des réseaux satellites et satellites-cellulaires hybrides. Soutenu par plusieurs licences et brevets américains et internationaux, le terminal Kymeta répond au besoin en systèmes de communication haut débit, légers et fins, qui ne nécessitent aucun composant mécanique pour s’orienter vers un satellite. Kymeta facilite la connexion pour tous les véhicules, navires ou plateformes fixes. Kymeta est une société privée basée à Redmond, dans l’État de Washington. Pour de plus amples informations, consultez kymetacorp.com. Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence. Consultez la version source sur businesswire.com :https://www.businesswire.com/news/home/20210209006101/fr/ CONTACT: Demandes d’informations commerciales concernant Kymeta : Jon Maron Vice-président du marketing et des communications Kymeta Corporation +1 425.658.8827 [email protected] d’informations de la part des médias concernant Kymeta : Amanda Barry Directrice adjointe des RP, The Summit Group [email protected] KEYWORD: EUROPE UNITED STATES NORTH AMERICA ASIA PACIFIC WASHINGTON INDUSTRY KEYWORD: TECHNOLOGY MOBILE/WIRELESS ENGINEERING SATELLITE TELECOMMUNICATIONS MANUFACTURING SOFTWARE NETWORKS HARDWARE SOURCE: Kymeta Corporation Copyright Business Wire 2021. PUB: 02/09/2021 02:32 PM/DISC: 02/09/2021 02:32 PM http://www.businesswire.com/news/home/20210209006101/frcenter_img TAGS  WhatsApp Facebook WhatsApp Twitter Local NewsBusinesslast_img read more